Syntaxin

Bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases.

placeAbingdon, England, United Kingdom calendar_todayFounded 2005 groups28 employees language syntaxin.com

Innovation

76 patent families (31 granted) — focus: Chemistry & metallurgy, Human necessities, Operations & transport, Physics & computing; filing pace slowing. Cited 5,304 times.

YearFilings
201221
201323
201421
201517
201610
20175
20183
20194
20203
20221

Social engagement

Social engagement: 318.4K social following, 9 posts in the last 12 months — below the industry typical range.

Investor mix

11 investors on record; 3 have since exited.

Investor typeCountShare
Venture capital545%
Private equity327%
Other / undisclosed327%

Recent activity

30 Jun 2026
Recognition
26 Jun 2026
Milestone
regulatory
24 Jun 2026
Event
ESPGHAN 2026
Coming soon